Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2015

View Archived Issues

Acquisitions: recent news

Auspherix raises financing to develop antibacterials

Pluristem receives support from Israeli government to develop PLX-PAD in Japan

Collaborations: recent news

Phase III study finds biosimilar BCD-021 equivalent to Avastin in NSCLC

Phase III trial of dendritic cell vaccine for RCC recommended to continue

Enrollment complete in Apios's phase I/II trial of bryostatin-1 in HIV infection

Casi seeks Chinese approval to begin phase II trial of ENMD-2076 in fibrolamellar carcinoma

EMA committee adopts positive opinion on pediatric investigation plan for Viaskin Peanut

Arno Therapeutics enters into CRADA with the U.S. Army to study the antiviral activity of AR-12

Catabasis reports preliminary phase I data on CAT-2054 for hypercholesterolemia

RESONATE-2 trial of ibrutinib in CLL/SLL meets key endpoints

ATF6 may have a relevant role in the development of achromatopsia

Symbiotix Biotherapies awarded NIAID grant to develop microbiome-derived therapeutics

Ardelyx regains rights to tenapanor, raises investment and reveals hyperkalemia candidates

FDA clears IND for clinical trials of Q-Cells for ALS

Janssen initiates rolling BLA submission for daratumumab in multiple myeloma

Nihon Medi-Physics and University of Kyoto patent diagnostics for aldosteronism

Verona Pharma advances clinical study of new nebulized formulation of RPL-554 for COPD

Wroclaw Research Centre EIT+ presents new compounds to treat infection

Corcept Therapeutics discloses GR modulators

Allergan presents FPR2 modulators

Rhythm initiates phase II trials of setmelanotide in Prader-Willi syndrome and POM-null obesity

Scientists disclose phase I results for G-305

FDA gives clearance to Roche's cobas HSV 1 and 2 test

Encouraging phase II data reported for selinexor in gynecological malignancies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...